For two decades, leukemia stem cells (LSCs) in chronic myeloid leukemia (CML) and acute myeloid leukemia (AML) have been advanced paradigms for the cancer stem cell field. In CML, the acquisition of the fusion tyrosine kinase BCR-ABL1 in a hematopoietic stem cell (HSC) drives its transformation to become a LSC. In AML, LSCs can arise from multiple cell types through the activity of a number of oncogenic drivers and pre-leukemic events-adding further layers of context and genetic and cellular heterogeneity to AML LSCs that is not observed in most cases of CML. Furthermore, LSCs from both AML and CML can be refractory to standardof-care therapies and persist in patients, diversify clonally, and serve as reservoirs to drive relapse, recurrence or progression to more aggressive forms. Despite these complexities, LSCs in both diseases share biological features, making them distinct from other CML or AML progenitor cells and from normal HSCs. These features may represent Achilles' heels against which novel therapies can be developed. Here, we